IMMX Key Statistics, Chart & Performance
The current stock price of IMMX is 5.095 USD. In the past month the price increased by 5.37%. In the past year, price increased by 142.86%.
IMMX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.52 | 392.88B | ||
| AMGN | AMGEN INC | 14.82 | 174.55B | ||
| GILD | GILEAD SCIENCES INC | 14.76 | 150.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.51B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 776.92 | 52.35B | ||
| INSM | INSMED INC | N/A | 36.97B | ||
| NTRA | NATERA INC | N/A | 33.77B | ||
| BIIB | BIOGEN INC | 10.45 | 25.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.76 | 21.32B | ||
| INCY | INCYTE CORP | 16.18 | 20.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About IMMX
Company Profile
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Company Info
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA US
Employees: 20
Phone: 18889581084
IMMIX BIOPHARMA INC / IMMX FAQ
What does IMMX do?
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
What is the stock price of IMMIX BIOPHARMA INC today?
The current stock price of IMMX is 5.095 USD. The price decreased by -0.1% in the last trading session.
Does IMMIX BIOPHARMA INC pay dividends?
IMMX does not pay a dividend.
What is the ChartMill rating of IMMIX BIOPHARMA INC stock?
IMMX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting IMMX stock to perform?
7 analysts have analysed IMMX and the average price target is 12.24 USD. This implies a price increase of 140.24% is expected in the next year compared to the current price of 5.095.
Can you provide the sector and industry classification for IMMIX BIOPHARMA INC?
IMMIX BIOPHARMA INC (IMMX) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for IMMX stock?
IMMIX BIOPHARMA INC (IMMX) will report earnings on 2026-03-23, after the market close.
IMMX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMMX. When comparing the yearly performance of all stocks, IMMX is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
IMMX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMMX. The financial health of IMMX is average, but there are quite some concerns on its profitability.
IMMX Financial Highlights
Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 9.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.34% | ||
| ROE | -285.09% | ||
| Debt/Equity | 0 |
IMMX Forecast & Estimates
7 analysts have analysed IMMX and the average price target is 12.24 USD. This implies a price increase of 140.24% is expected in the next year compared to the current price of 5.095.
For the next year, analysts expect an EPS growth of -5.01% and a revenue growth -100% for IMMX